Stock Screener App

무료 -

설치하다

0.00

100.00% -53.01

Soleno Therapeutics Inc (SLNO)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews

Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P - TradingView

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review

Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily

2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation | Press Release - Stockhouse

Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Soleno Therapeutics (SLNO) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits

Soleno Therapeutics (SLNO) Q4 2025 earnings summary - Quartr

Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary - Quartr

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Steady Performance with Limited Upside in the Biotech Sector - DirectorsTalk Interviews

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire

Soleno Therapeutics Inc. Investors with Substantial Losses Have O - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Stable Horizon with Strong Cash Reserves - DirectorsTalk Interviews

How Soleno Therapeutics Inc. (SLNO) Affects Rotational Strategy Timing - Stock Traders Daily

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirt - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire

2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect | Press Release - Stockhouse

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating the Biotech Sector with a Strong Free Cash Flow - DirectorsTalk Interviews

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Soleno Therapeutics Inc (SLNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire

2026-06-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse

Soleno Therapeutics Inc (SLNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out - ACCESS Newswire

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Evaluating The Biotech's Steady Trajectory - DirectorsTalk Interviews

3-year VYKAT XR trial eases hyperphagia, behaviors in PWS - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory - DirectorsTalk Interviews

SLNO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Soleno Therapeutics (SLNO) Holds Steady at $53.01: Consolidation Within Key BoundariesFactor Crowding - newsline.com

Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia

NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact - TradingView

Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com Canada

Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating Zero Upside but Strong Cash Flow - DirectorsTalk Interviews

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out - ACCESS Newswire

SLNO Technical Analysis & Stock Price Forecast - Intellectia AI

2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out | Press Release - Stockhouse

[15-12G] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan

[EFFECT] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan

Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN

Soleno Therapeutics (SLNO) Investor Outlook: Navigating the Hold Ratings with Promising EPS and Cash Flow - DirectorsTalk Interviews

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan

SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo

Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000 Growth Index - marketscreener.com

INSM

$109.14

5.60%

ROIV

$34.51

4.06%

RPRX

$56.45

0.04%

MRNA

$67.01

1.85%

ONC

$303.96

1.76%

ALNY

$288.06

3.58%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개